Septic Shock Clinical Trial
Official title:
Assessing Targeted Fluid Resuscitation Strategies Among Patients With Severe Sepsis and Septic Shock
IV fluid resuscitation has long been recognized to be an important treatment for patients with severe sepsis and septic shock. While under-resuscitation is known to increase morbidity and mortality, contemporary data suggests that overly aggressive fluid resuscitation may also be harmful. Currently, following an initial IVF resuscitation of 30 ml/kg, there is no standard of care and a lack of evidence to support a fluid restrictive or more liberal strategy. The investigators seek to determine if a fluid restrictive strategy reduces morbidity and mortality among patients with severe sepsis and septic shock.
Sepsis is one of the most common indications for intensive care unit admission world wide and
the third leading cause of death in the United States. While IV fluid administration has been
recognized as an important part of sepsis resuscitation for over 15 years, there is growing
concern that overly aggressive IV fluid resuscitation may be harmful to patients with severe
sepsis and septic shock.
The current standard of care for initial resuscitation is outlined in the 2016 Surviving
Sepsis guidelines which recommends a 30mL/kg bolus of IV fluid for septic patients with
hypotension (mean arterial pressure <65 mm Hg) or a lactic acid >4mmol/L within the first 3
hours of presentation. This standard is affirmed by the 2015 Centers for Medicare & Medicaid
(CMS) SEP-1 guidelines. Afterwards, the guidelines advise the use of vasopressors to maintain
a mean arterial pressure (MAP) of >65 mm Hg within the first 6 hours of patient care.
Following the initial 30mL/kg bolus, there is no established standard of care for fluid
administration; therefore there is significant variation in care between providers and
institutions. Currently, there is no human data that indicates that larger volume (>30mL/kg)
resuscitation strategy improves blood pressure or end organ perfusion , yet it is not
uncommon for patients to receive large volumes of IV fluid (5-10 liters) in the early stages
of resuscitation.
When considering how much IV fluids are typically administered to patients with septic shock,
examination of the large EGDT RCTs provides a more informed picture. In the original Rivers
study patients received approximately 70 mL/kg of IVF in the first 6 hours and additional 125
ml/kg in hours 7 to 72.3 Notably, this large volume resuscitation did not produce increased
rates of clinically important heart failure and intubation. In the contemporary EGDT
validation trials, patients received 60-70 ml/kg of IVF in the first 6 hours and only 60-70
ml/kg from hours 7 to 72.6,7,8 The contemporary alternative approach being advocated among
critical care practitioners is to use vasopressors to maintain a mean arterial pressures
above 65 mm Hg following the initial 30 ml/kg bolus, thereby maintaining organ perfusion,
while limiting further IV fluid administration.9 Without clear evidence to guide physicians
under current usual care the amount of IV fluid administration varies widely between
providers and institutions when resuscitating patients with severe sepsis and septic shock.
The investigators hypothesize the use of a fluid restrictive strategy will result in a lower
28-day mortality, ICU length of stay and total number of ventilator days but will not reduce
the number of patients who need hemodialysis or require intubation.
The primary outcome of the study is to assess if a restrictive IV fluid resuscitation
strategy has a composite benefit of a reduced discharge mortality or Persistent Organ
Dysfunction (POD) score compared to a usual care among patients with severe sepsis and septic
shock. POD is defined by the ongoing need for vasopressor agents such as norepinephrine,
epinephrine, vasopressin or dopamine for more than two hours in a given day; persistent renal
failure as defined by the need for any ongoing renal replacement therapy; and persistent
respiratory/neuromuscular failure as defined by the ongoing need for mechanical ventilation
(not including non-invasive ventilation modalities).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03649633 -
Vitamin C, Steroids, and Thiamine, and Cerebral Autoregulation and Functional Outcome in Septic Shock
|
Phase 1/Phase 2 | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Completed |
NCT05629780 -
Temporal Changes of Lactate in CLASSIC Patients
|
N/A | |
Recruiting |
NCT04796636 -
High-dose Intravenous Vitamin C in Patients With Septic Shock
|
Phase 1 | |
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Recruiting |
NCT05066256 -
LV Diastolic Function vs IVC Diameter Variation as Predictor of Fluid Responsiveness in Shock
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 | |
Not yet recruiting |
NCT04516395 -
Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae
|
N/A | |
Recruiting |
NCT02899143 -
Short-course Antimicrobial Therapy in Sepsis
|
Phase 2 | |
Recruiting |
NCT02676427 -
Fluid Responsiveness in Septic Shock Evaluated by Caval Ultrasound Doppler Examination
|
||
Recruiting |
NCT02565251 -
Volemic Resuscitation in Sepsis and Septic Shock
|
N/A | |
Recruiting |
NCT02580240 -
Administration of Hydrocortisone for the Treatment of Septic Shock
|
N/A | |
Completed |
NCT02638545 -
Hemodynamic Effects of Dexmedetomidine in Septic Shock
|
Phase 3 | |
Terminated |
NCT02335723 -
ASSET - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber
|
N/A | |
Not yet recruiting |
NCT02547467 -
TOADS Study: TO Assess Death From Septic Shock.
|
N/A | |
Completed |
NCT02079402 -
Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care
|
Phase 4 | |
Completed |
NCT02204852 -
Co-administration of Iloprost and Eptifibatide in Septic Shock Patients
|
Phase 2 |